Conditions: Chronic Myelogenous Leukemia Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Allocation:  | Intervention model: PARALLEL
Enrollment: 54
Healthy volunteers: no

Brief summary:
To assess the safety of dasatinib (BMS-354825) in subjects with Imatinib resistant or intolerant chronic myelogenous leukemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) who are resistant or intolerant to treatment and will continue study drug after completing the previous Phase I/II study (CA180031/NCT00337454)

Detailed description:

Arms:
arm 1: CML - Chronic Phase arm 2: CML - Accelerated Phase and Blast Phase arm 3: Ph+ Acute Lymphoblastic Leukemia

Interventions: intervention 1: dasatinib
Intervention descriptions: intervention 1: Tablet, Oral, (50mg, 70mg or 90mg BID on a continuous daily dosing schedule), allowed to modify within the range of 50 mg twice daily (BID) to 90 mg BID

Protocol document: